Physician profile
Ariel Eber
NPI 1245728708
$2,339.09
in general payments reported to CMS, 2019-2025
16 companies · $580 in 2025
The $580 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $707 · 2023: $556 · 2024: $496 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,631.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $760.44 | 2022-2024 | Rinvoq, Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $434.59 | 2022-2023 | Sotyktu |
| Galderma Laboratories, L.P. | $338.58 | 2025 | Nemluvio |
| Musculoskeletal Transplant Foundation INC. | $186.68 | 2024-2025 | |
| Allergan, INC. | $105.52 | 2022 | |
| Incyte Corporation | $83.65 | 2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.28 | 2022-2023 | Spevigo |
| Janssen Biotech, INC. | $68.16 | 2024-2025 | Tremfya |
| Amgen INC. | $53.59 | 2023 | Otezla |
| Arcutis Biotherapeutics, INC. | $51.83 | 2024-2025 | Zoryve |
| Pfizer INC. | $50.77 | 2022-2023 | |
| Genzyme Corporation | $36.15 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $27.00 | 2023 | Libtayo |
| Ucb, INC. | $21.73 | 2023 | Cimzia |
| Leo Pharma INC. | $20.04 | 2023 | Adbry |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $19.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariel Eber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.